Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed the day trading at $10.69 down -1.75% from the previous closing price of $10.88. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 4.26 million shares were traded. SPRY stock price reached its highest trading level at $11.0263 during the session, while it also had its lowest trading level at $10.33.
Ratios:
For a better understanding of SPRY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.98 and its Current Ratio is at 6.17. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Roth Capital on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $40.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.Oppenheimer initiated its Outperform rating on February 10, 2025, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’25 when Lowenthal Richard E sold 50,000 shares for $14.49 per share. The transaction valued at 724,345 led to the insider holds 1,196,494 shares of the business.
Scott Kathleen D. sold 12,500 shares of SPRY for $187,500 on Aug 21 ’25. The Chief Financial Officer now owns 10,042 shares after completing the transaction at $15.00 per share. On Aug 20 ’25, another insider, Tanimoto Sarina, who serves as the CHIEF MEDICAL OFFICER of the company, sold 37,656 shares for $14.09 each. As a result, the insider received 530,626 and left with 1,247,447 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1075232256 and an Enterprise Value of 889943552. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.40 while its Price-to-Book (P/B) ratio in mrq is 5.49. Its current Enterprise Value per Revenue stands at 7.922 whereas that against EBITDA is -15.152.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.87, which has changed by -0.058978856 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $10.00. The 50-Day Moving Average of the stock is -34.06%, while the 200-Day Moving Average is calculated to be -22.68%.
Shares Statistics:
Over the past 3-months, SPRY traded about 1.78M shares per day on average, while over the past 10 days, SPRY traded about 3379290 shares per day. A total of 98.70M shares are outstanding, with a floating share count of 58.37M. Insiders hold about 40.94% of the company’s shares, while institutions hold 62.83% stake in the company. Shares short for SPRY as of 1755216000 were 17765896 with a Short Ratio of 9.99, compared to 1752537600 on 14864141. Therefore, it implies a Short% of Shares Outstanding of 17765896 and a Short% of Float of 29.29.
Earnings Estimates
The performance of ARS Pharmaceuticals Inc (SPRY) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.13 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.61 and -$1.92 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$0.86, with 4.0 analysts recommending between -$0.68 and -$1.07.
Revenue Estimates
6 analysts predict $28.53M in revenue for the current quarter. It ranges from a high estimate of $32.49M to a low estimate of $25.6M. As of the current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $2.07MFor the next quarter, 6 analysts are estimating revenue of $30.63M. There is a high estimate of $38.6M for the next quarter, whereas the lowest estimate is $21.5M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $87.7M, while the lowest revenue estimate was $74.9M, resulting in an average revenue estimate of $81.64M. In the same quarter a year ago, actual revenue was $89.15MBased on 7 analysts’ estimates, the company’s revenue will be $208.47M in the next fiscal year. The high estimate is $262.4M and the low estimate is $117.6M.
